Related references
Note: Only part of the references are listed.Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Tammy F. Chu et al.
LANCET (2007)
Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome
E. Kapiteijn et al.
ANNALS OF ONCOLOGY (2007)
Reversible posterior Leukoencephalopathy syndrome induced by sunitinib
German Martin et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis
Xiaolei Zhu et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
Sunitinib in patients with metastatic renal cell carcinoma
Robert J. Motzer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer
M Kosugi et al.
CLINICAL CANCER RESEARCH (2006)
Mechanisms of hypertension associated with BAY 43-9006
ML Veronese et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Controversies in cardiology 2 - Controversies in hypertension
NM Kaplan et al.
LANCET (2006)
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Antagonism of the renin-angiotensin system can counteract cardiac angiogenic vascular endothelial growth factor gene therapy and myocardial angiogenesis in the normal heart
AJ Siddiqui et al.
AMERICAN JOURNAL OF HYPERTENSION (2005)
Nifedipine-induced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes endothelial tube formation via the kinase insert domain-containing receptor/fetal liver kinase-1/NO pathway
Shin-ichiro Miura et al.
HYPERTENSION RESEARCH (2005)
Rhebbing up mTOR - New insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis
DJ Kwiatkowski
CANCER BIOLOGY & THERAPY (2003)
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
AM O'Farrell et al.
BLOOD (2003)
Structural and functional changes of the microcirculation in hypertension: Influence of pharmacological therapy
E Agabiti-Rosei
DRUGS (2003)
SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model
LJ Murray et al.
CLINICAL & EXPERIMENTAL METASTASIS (2003)
Share Paper
